Northwire Canada EditionSaturday, October 17, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Regulatory

MindBio Lists for Trading on OTCQB Market

By The Northwire Desk — AI Analysis Jan 21, 2026 · 10:10 MBIO · 1.1 MindBio Therapeutics Corp.
MBIO · Price

Executive Summary

  • MindBio Therapeutics Corp. announced that its common shares are now listed for trading on the OTCQB market.
  • The listing coincides with the launch of an extended U.S. roadshow promoting its AI‑driven voice technology for drug and alcohol intoxication detection.
  • CEO Justin Hanka highlighted the expanded access to U.S. investors interested in AI and predictive health technologies.

Key Details

  • Listing: Common shares now trade on the OTCQB market under ticker MBQIF.
  • Roadshow: An extended roadshow in the United States will showcase MindBio’s voice‑and‑AI intoxication detection platform to potential investors, partners, and customers.
  • Technology Highlight: The company has developed an AI model using >50 million data points that predicts alcohol intoxication from voice alone and estimates blood alcohol concentration; a consumer “Booze AI” app is slated for launch in 2025.
  • Enterprise Expansion: MindBio is developing an enterprise version of the platform targeting workplaces, call centres, mental‑health services, and law‑enforcement applications.
  • Future Announcements: The company expects to provide updates on new products, market expansions, and commercial opportunities in the near term.
  • CEO Quote: “We are pleased to now reach US investors and a much larger investor audience, particularly those US investors interested in AI and predictive health technologies via our OTCQB listing.” – Justin Hanka, CEO

Notable Quotes

  • “We are pleased to now reach US investors and a much larger investor audience, particularly those US investors interested in AI and predictive health technologies via our OTCQB listing.” – Justin Hanka, Chief Executive Officer.
Read the original news release →

More from MindBio Therapeutics Corp.

Jun 09, 2026 · 07:00

From failed psychedelics to unproven AI kiosks: MindBio bets its survival on voice analytics, but cash burn and dilution loom.

Production / Operations Jun 04, 2026 · 11:12

MindBio’s Voice AI Pivot Buys Time, But Cash Runway and Dilution Risk Keep the Stock in the Red Zone

Other May 15, 2026 · 08:30

MindBio's AI Pivot Masks Failed Drug Trial and Dilution Risk

Other May 14, 2026 · 08:30

MindBio Pivots from Failed Psychedelic Trial to AI Voice Detection Amidst Dilution Concerns

Other May 13, 2026 · 08:30

MindBio Pivots to AI Voice Tech After Clinical Setback; Dilution Risks Loom

Other May 11, 2026 · 08:45

MindBio Pivots from Clinical Failure to AI Voice Analytics, But Dilution Risks Loom

Other